ISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual
|
|
- Quentin Winfred Hunter
- 6 years ago
- Views:
Transcription
1 The StAmP Trial: A Proof of Principle, double blind, Randomised Placebo-Controlled, Multi Centre Trial of Statins to Ameliorate Early Onset Pre-eclampsia. ISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350 StAmP Pharmacy Manual V1.1 14Jan2011 Page 1 of 11
2 TABLE OF CONTENTS 1. Pharmacy Responsibilities Trial IMP Description IMP Supply and Ordering IMP costs IMP labelling IMP Storage Route of Administration, Dosage, Dosage Regimen and Treatment Period Patient Randomisation Unblinding IMP Receipt IMP Accountability and Reconciliation IMP Return and Destruction Monitoring Archiving Reports/Correspondence StAmP Pharmacy Manual V1.1 14Jan2011 Page 2 of 11
3 1. Pharmacy Responsibilities A pharmacist must be named and must sign the site Trial Signature & Delegation Log, a copy of which is provided in section 3 of the Site File. The Site File is kept by the Principal Investigator. All personnel responsible for the receipt, storage, dispensation and destruction of trial medication must also sign this form. This form must also be co-signed by the site s Principal Investigator. Once complete, a copy of the form must be returned to the StAmP Trial office. The original must be retained in section 3 of the Site File. New site personnel accepting responsibilities can then be added to the form if required. Please ensure that the StAmP Trial office is informed of any changes in the contact details for the responsible pharmacist. Should the responsible pharmacist change, the Trial Signature & Delegation Log must be updated and forwarded to the StAmP Trial office. 2. Trial IMP Description The investigation medicinal product (IMP) is pravastatin, as 40mg pravastatin sodium as a capsule. The most recent Summary of Product Characteristics for pravastatin can be found at Blinding of Pravastatin 40mg tablets will be carried out by the process of over-encapsulation. One entire tablet will be placed inside a size 00 opaque hard gelatine capsule. A Lactose / 1% Magnesium Stearate blend will be added to stop the tablet rattling inside the capsule. The placebo will be a placebo capsule, encapsulated in the same format as the IMP to be identical in colour, shape and weight. A matching size 00 opaque hard gelatine capsules will be filled with Lactose / 1% Magnesium Stearate blend alone to produce placebo capsules for the study. 3. IMP Supply and Ordering The study drug will be supplied, packaged and distributed by Bilcare (UK) Ltd using their clinical trial drug distribution procedures. Bilcare will procure Pravastatin inspecting the certification of the IMP supplied by the manufacturer (Teva Ltd) and retaining one original blister pack per batch as reference. Bilcare will overencapsulate the IMP and placebo and package accordingly. Each treatment pack will consist of a resistant tamper evident container and will contain 28 capsules for use by an individual subject only. A pack MUST NOT be shared by two or more subjects. Container dimensions are approximately 8 x 5 x 5 cm. Pharmacies should provide full details of where the drug is to be delivered to and a contact name and number for the courier to call in the event of any problems Pravastatin and Placebo Supply At study initiation, Birmingham Clinical Trials Unit will arrange an initial supply of Pravastatin and placebo to be automatically shipped by Bilcare (UK) Ltd to the pharmacist at the trial site. Each trial site will receive an initial supply of 8 treatment packs (4 of Pravastatin and 4 of Placebo). (The total number may vary depending on anticipated recruitment rates at the trial centre.) Box dimensions are approximately 8 x 5 x 5 cm. StAmP Pharmacy Manual V1.1 14Jan2011 Page 3 of 11
4 Bilcare will provide the QP release service prior to delivery under the requirements of the Medicines for Human Use (Clinical Trials) Regulations 2004 and the amendments Trial Drug Re-supply Re-supply of pravastatin and placebo will be managed manually. Birmingham Clinical Trials Unit (BCTU) will be informed when a patient has been randomised to the study. This information will be tracked to allow calculation of available supplies on site. This will prompt BCTU to verify that pravastatin and placebo supply levels at site are sufficient. If supply quantities are not adequate, BCTU will contact Bilcare accordingly. In addition, if it is noticed at site that supplies are getting low and additional trial drug supply is needed, please contact the BCTU who will be able to request a resupply. A re-supply will consist of 8 treatment packs (4 of Pravastatin and 4 of Placebo). (The total number may vary depending on anticipated recruitment rates at the trial centre.) Bilcare will provide the QP release service prior to delivery under the requirements of the Medicines for Human Use (Clinical Trials) Regulations 2004 and the amendments. It is assumed that for the majority of participants, delivery will occur within 28 days of randomisation. However, in case some deliveries occur later than 28 days post-randomisation, continuation trial drug packs will be available. Should it be considered likely, at 21 days post-randomisation,that the pregnancy will continue beyond 28 days, the Principal Investigator or other clinical investigator must contact BCTU to arrange have a continuation pack, containing 28 capsules to be labelled and dispatched to the centre. Should a treatment pack be lost or damaged post-randomisation, a replacement drug treatment pack can be obtained by the pharmacist by the same mechanism. The reason must be documented on the StAmP Drug Accountability Log (see section 11) and fully investigated if appropriate. 4. IMP costs The trial drug will be provided free of charge. The cost of Pravastatin and placebo is covered by the StAmP Trial. 5. IMP labelling The drug will be labelled by Bilcare in compliance with regulatory requirements (Annex 13) and will have been submitted to the competent authority as part of the Clinical Trial Authorisation process, so should be consistently applied. Any addition or modification to the label apart from the variable data must be authorized by the Sponsor. Pravastatin/ Placebo bottle labels for the study are displayed below. (Note: that V denotes variable information). StAmP Pharmacy Manual V1.1 14Jan2011 Page 4 of 11
5 6. IMP Storage 6.1. Storage Conditions Pravastatin and placebo should be stored in a dry place at a temperature of 15 o - 30 o C Stability of trial drugs The shelf life for pravastatin and placebo is 36 months when stored at 15 o - 30 o C. No IMP can be dispensed beyond the expiry date Temperature Deviation Pravastatin and placebo should be stored 15 o - 30 o C. Provision must be in place to store the IMP within the permitted temperature range. Temperature must be monitored regularly. Ideally, a continuing electronic monitoring system (24/7) is expected. However it is acceptable to use a well maintained system of max min thermometer recording at least once per working day. Diligence is expected in checking that at the time of dispensing, the IMP has always been stored in the permitted range. Whichever system is adopted the equipment must be regularly calibrated and a certificate of recalibration be available to the Sponsor or StAmP Trial Office at least once a year. Temperature logs should be maintained at all times. Temperature logs must be available for inspection by the monitoring team, when requested at monitoring visits. Should there be a deviation in the storage temperature of the trial drug, it must be immediately quarantined. The StAmP trials office should also be notified immediately of the deviation and sites will be instructed accordingly. The deviation must be recorded on the Temperature Deviation Form, copies of which are provided in section 4 of the Pharmacy Site File. The Investigator should be immediately contacted and eventual IMP already dispensed recalled. Patient safety should be managed according to GCP. 7. Route of Administration, Dosage, Dosage Regimen and Treatment Period A single capsule must be taken as once daily in the evening, orally with or without food. On the day of randomisation, the first dose should be given that evening. If a patient is randomised too late in the evening, the first dose may be given the following evening. Treatment should continue daily in the evening until the pregnancy is ended. StAmP Pharmacy Manual V1.1 14Jan2011 Page 5 of 11
6 If it is clear that the tablet has not been absorbed, i.e. vomited up within 2 hours, then they should have another tablet. If the tablet is missed by less than 18 hours, a further tablet should be taken. 8. Patient Randomisation Pharmacy notification of patient randomisation will be sent immediately by following randomisation from the Birmingham Clinical Trials Unit (BCTU) to the pharmacy responsible for dispensing the trial drug to the patient. The notification will confirm the following details: Patient initials Date of Birth Hospital Number Date of Randomisation Trial Number Bottle Number The bottle number provided will correspond to a drug treatment pack available in the hospital pharmacy. On receipt of randomisation notification, the pharmacist will prepare the drug treatment pack for dispensing. The treatment pack will contain 28 capsules for use by one participant. The pharmacist should complete the pack label with the following details before dispensing: Patient Initials Patient Trial Number Investigator Site Date of Dispensing Randomisation acknowledgement s should be filed in section 5 of the Pharmacy Site File. 8.1 Allocation of Treatment in event of a Manual Paper Randomisation In the unlikely event of the computer system being unavailable to perform the randomisation, a manual paper randomisation will be performed. In such cases, the Clinical Investigator/ Research Midwife will notify the Pharmacist that a manual randomisation is required. The Pharmacist should then randomly select any available treatment pack. The Pharmacist should notify the Clinical Investigator/ Research Midwife of the selected bottle number. They will need to relay this information to the StAmP Trial Office. The expiry date on pack allocated manually must be checked to ensure that it is not within 1 month of dispensing. Birmingham Clinical Trials Unit (BCTU) will send a fax with paper randomisation confirmation. The pharmacist should complete the pack label as above before dispensing. Once computer system is available again, a randomisation acknowledgement will be sent. These should be filed in section 5 of the Pharmacy Site File as above. StAmP Pharmacy Manual V1.1 14Jan2011 Page 6 of 11
7 9. Unblinding Participants, investigators, research midwives and other attending clinicians will remain blind to the trial drug allocation for the duration of the trial and will not have access to the trial number-treatment allocation code for the duration of the interventional phase of the trial. Should a serious, adverse event occur, management and care of the women should be initiated as though the woman was taking pravastatin. Cases that are considered serious, unexpected and possibly, probably or definitely related (i.e. possible SUSARs - see Section 7 of the protocol) should be unblinded only at the Trial Office by the StAmP Trial Coordinator. The attending clinician and local PI will not be made aware of the actual trial drug. Investigators and research midwives should remain blind to drug allocation as far as possible, however if the drug allocation is required for the medical management of particular patients, clinicians should contact the StAmP Trial Office. Alternatively, use the online StAmP code-break system. This service will be available 24 hours a day, 7 days a week. FOR UNBLINDING Online (You will need your username and password) OR Contact the StAmP Trial Office on Tel: (office hours only) 10. IMP Receipt Each shipment will contain one Packing Slip and Shipment Receipt Confirmation. The pharmacist must sign the receipt confirmation verifying the quantity and condition of the supplies received. The pharmacist must then fax a copy of the signed receipt confirmation to Bilcare to the number indicated AND fax a copy to the StAmP Trial Office on Please retain all transmission forms. The Pharmacist must retain the original signed confirmation in section 4 of the Pharmacy File. The Packing Slip and Shipment Receipt Confirmation is required to document that the site received the trial drug in good condition and in the quantity noted. When a shipment is received, please inventory, inspect and verify the contents of the shipment for the following: Ensure the shipment is received free from damage. Ensure that the drug shipped is what is recorded on the form. Make sure that total quantity received is as listed on the form. Verify that the tamper evident seal is intact on the individual bottles. Conduct a thorough inspection of the shipment and mark the condition of drug as it was received. If applicable, contact Bilcare immediately for any problems relating to the shipment of trial drug. Provide the problem information in the comments area provided on the form. If everything is in order, please sign and date the form. ALL consignments of trial drug, whether in good condition or damaged, MUST be confirmed. Retain the original signed Packing Slip and Shipment Receipt Confirmation in the Pharmacy File. If there is a problem with the shipment, contact Bilcare immediately notifying them of the problem. Provide the problem information in comments area provided on the Packing Slip and Shipment StAmP Pharmacy Manual V1.1 14Jan2011 Page 7 of 11
8 Receipt Confirmation and fax all pages of the letter on the day you receive the product to the number indicated on the form. 11. IMP Accountability and Reconciliation Trial Drug Accountability Logs are provided in section 4 of the Pharmacy Site file. Accurate records of all drugs dispensed must be maintained. These records must be available for inspection by representatives of the StAmP Trial Office or UCL as sponsor at any time. Drug supplies are to be used only in accordance with this protocol and under the supervision of the Investigator. The study pharmacist should ensure that a clear log of the investigational product dispensed is maintained throughout the study. We would like you to use our trial specific forms. Upon receipt of trial drugs, complete the StAmP Drug Accountability Log with the relevant information about number of packs, batch number, expiry date and increasing the New Total in Stock by the number of packs that have been received. When dispensing drugs to a patient, ensure that the patient details are completed, and the New Total in Stock is reduced by the amount dispensed. Drugs returned to the pharmacy after dispensing must not be re-used. Keep medication returned from patients separate from trial stocks. Complete the StAmP Drug Accountability Log by ticking the Return box and filling in the information about number of capsules returned, batch and expiry date but DO NOT add the number returned to the New Total in Stock. Returned medication must be destroyed in a documented manner. To document destruction, complete the StAmP Drug Accountability log by ticking the Destruction box, and filling in the information about the number of capsules, batch and expiry date but DO NOT deduct the number destroyed from the New Total in Stock. Record any information relevant to the destruction in the comments section e.g. Returned medication destroyed as per local policy. When there is a requirement to destroy drugs from stock e.g. expired or damaged stock, document the destruction on the StAmP Drug Accountability Log by ticking the Destruction box, and filling in the information about the number of packs, batch and expiry date. Remember to deduct the number destroyed from the New Total in Stock. Record any information relevant to the destruction in the comments section e.g. Expired stock medication destroyed with permission of the Sponsor as per local policy. Use continuation sheet if first sheet is full. Ensure to add page number to the footer. Ensure any completed logs are ultimately stored in the Investigator Site File and copies are forwarded to the StAmP Trial Office as per instruction. Note that during the trial, the trial completed logs may be stored in the Pharmacy File. Any discrepancies must be documented and subsequently reported to the StAmP Trial Office immediately. These inventories must be made available for inspection by authorized representative(s) of UCL as sponsor, the StAmP Trial Office, and regulatory agency inspector(s). The Investigator is responsible for the accountability of all used and unused trial supplies. StAmP Pharmacy Manual V1.1 14Jan2011 Page 8 of 11
9 Drug accountability records must be completed by the pharmacist or designee and kept up-to-date. Investigational product accountability/reconciliation should be performed regularly. 12. IMP Return and Destruction Returned and unused packs of trial drug must be destroyed according to hospital procedures and be properly accounted for in the StAmP Drug Accountability Log filed in section 4 of the Pharmacy Site File as detailed above in Section 11. Return of used investigational product should be managed on a regular basis to prevent a back-log of used trial drug at site pharmacy. The timing of returns is more often than not dictated by the site s storage capabilities. Note: Trial drug can only be destroyed on site if the site has a documented procedure and the sponsor or the StAmP Trial Office has given appropriate approval in writing. A copy of the documented procedure for destruction will need to be provided to the StAmP Trial Office and a copy should be retained in the Pharmacy File IMP return and destruction at Bilcare When it is not possible for the site to destroy used or unused trial drug on site, it can be returned to Bilcare for destruction. The trial pharmacist should ensure a clear log is kept on the StAmP Drug Accountability Log. When there is a requirement to return used trial drug to Bilcare, document the return by ticking the Return to Bilcare box, and filling in the information about the number of capsules, batch and expiry date but DO NOT deduct the number returned from the New Total in Stock. Record any information relevant to the return in the comments section e.g. Returned medication returned to Bilcare for destruction. When there is a requirement to return drugs from stock e.g. expired or damaged stock drug to Bilcare for destruction, document the return by ticking the Return to Bilcare box, and filling in the information about the number of packs, batch and expiry date. Remember to deduct the number destroyed from the New Total in Stock. Record any information relevant to the return in the comments section e.g. Expired stock medication returned to Bilcare with permission of the Sponsor as per local policy. A Return of Trial Drug for Destruction Form must also be completed and included in the shipment of used and unused investigational product to Bilcare. Return of Trial Drug for Destruction Forms are filed in section 4 of the Pharmacy Site File. Ensure name of the Principal Investigator, Site and name of the Lead Pharmacist is correctly detailed. Enter the complete batch number, expiry date and bottle number When returning used drug after dispensing, enter the number of capsules returned for destruction When returning unused drug e.g. expired or damaged stock, check the unused column The completed form is to be signed and dated by the individual verifying and returning the product. A copy will be returned to Bilcare enclosed with the return shipment, and the original remains at the site in the Pharmacy Binder. StAmP Pharmacy Manual V1.1 14Jan2011 Page 9 of 11
10 A Bilcare Collection Request Form must be completed and faxed to Bilcare to initiate a collection. Enter University of Edinburgh as Customer Reference Number Enter StAmP as Study Reference Ensure complete details on contact at pick up and collection address details. On receipt of the Collection Request Form, Bilcare will contact pharmacy contact to arrange the collection date and details. At the end of the study, the Final Investigational Product Reconciliation Statement must be completed and provided to the StAmP Trial Office. 13. Monitoring The StAmP Trial will be monitored by the StAmP Trial Coordinator from the StAmP Trial Office. Monitoring may also be performed by representatives of UCL as the Sponsor or representatives of the regulatory authorities. 14. Archiving The Pharmacy Site file for the StAmP Trial should be archived along with all the essential trial documentation and source records (e.g. signed Consent Forms, Investigator and patients hospital notes, copies of Case Report Forms etc) at site and should be securely retained for at least 5 years (but ideally not less than 15 years) after the end of the trial. Participating sites will be sent a letter specifying the permissible disposal date. 15. Reports/Correspondence Please file the Monitor Visit Report for each monitoring visit in section 7 of the Pharmacy site File. The Monitor Visit Report documents activities performed and issues noted by a Monitor during an on-site monitoring visit. Please file follow up letters from monitoring visits also in section 7 of the Pharmacy Site File. Please file any general correspondence regarding the StAmP Trial in section 7 of the Pharmacy Site File. Thank you for your valued support of the StAmP Trial StAmP Pharmacy Manual V1.1 14Jan2011 Page 10 of 11
11 Should you have any queries or require further information, please contact: Chief Investigator Dr David Williams University College London Hospital Institute for Women s Health 74 Huntley Street London WC1E 6DD : : d.j.williams@ucl.ac.uk Sponsor University College London Contact Temi Giwa University College London Hospital Research and Development Office 1 st Floor, Maple House, Ground Floor Rosenheim Wing, 25 Grafton Way London WC1E 6DB : : t.giwa@ucl.ac.uk StAmP Trial Office Birmingham Clinical Trials Unit (BCTU) Trial Coordinator Miss Alex Furmston Birmingham Clinical Trials Unit Robert Aitken Institute University of Birmingham Edgbaston Birmingham B15 2TT : FAX: : a.t.furmston@bham.ac.uk StAmP Pharmacy Manual V1.1 14Jan2011 Page 11 of 11
The following scenario illustrates the supply, receipting and movement of ANODE packs. Allocation and shipment of IMP
Guidance Sheet 11 IMP Management and Stock Control Participants in the ANODE Trial will receive an intravenous (IV) dose of either co-amoxiclav or an unmatched inactive placebo (0.9% saline). This is an
More informationIMP Management and Accountability
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationContents 1. OVERVIEW APPLICABILITY TRIAL INFORMATION PHARMACY REGISTRATION & SET-UP PHARMACY ACTIVATION PATI
CONTACT DETAILS For further information on trial drugs, trial protocol, dosing, drug supply and distribution, please contact: Trial Coordinator Name: Trial Coordinator Phone: 020 7679 9860 Email: ctc.animate@ucl.ac.uk
More informationECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies
ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies SOP number: ECTU TM 17 Signature Date Authored by: Holly Ennis, Trial Manager 6 th Sept 2017 Reviewed by: Laura Forsyth, Trial Manager
More informationInvestigator Site File Index (CTIMP)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol Current version plus all previous versions (or provide file note to detail location of previous
More informationINVESTIGATIONAL DRUG MANAGEMENT OVERVIEW
NORTHWELL HEALTH OFFICE OF RESEARCH COMPLIANCE STUDY FEASIBILITY AND APPROVAL Where can I learn about the investigational drug? Protocol Investigator s brochure Product insert or prescribing information
More informationCode break is also known as breaking the blind and involves un-blinding a participant so that the treatment allocation is made known.
1. INTRODUCTION This SOP has been produced in accordance with Medicines for Human Use (Clinical Trials) Regulations 2004. This SOP will outline the procedure for breaking the study code in a NUH sponsored
More informationLOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office
LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1024 LU Study Closedown and End of Study Reporting for NHS Research Sponsored by Loughborough
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationInvestigational Medicinal Product (IMP) Management Standard Operating Procedure
Reference Number: UHB 040 Version Number: 3 Date of Next Review: 26 Apr 2019 Previous Trust/LHB Reference Number: T 363 Standard Operating Procedure Introduction and Aim This procedure is written to support
More informationPHARMACY, MEDICINES & POISONS BOARD
PHARMACY, MEDICINES & POISONS BOARD PHARMACY GUIDELINES FOR INVESTIGATIONAL DRUGS A. Purpose These guidelines are principally derived and adapted from guidelines from various sources within the SADC region.
More informationSPONSOR INVESTIGATIONAL MEDICINAL PRODUCT (IMP) MANAGEMENT
SPONSOR INVESTIGATIONAL MEDICINAL PRODUCT (IMP) MANAGEMENT DOCUMENT NO.: GS010 v1.0 AUTHOR: Vikki Young ISSUE DATE: 28 MAY 2018 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research &
More informationInvestigator Site File Index (Medical Devices)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol (Clinical Investigation Plan) Current version plus all previous versions (or provide file note
More informationMANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS
ANNEX 13 MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS Introduction Medicinal products intended for research and development trials are not at present subject either to marketing or manufacturing Community
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationI. Purpose. II. Definitions. Last Approval Date
Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics
More informationLouise Brook Clinical Trials Quality Monitor. Date
Details: Author: Louise Brook Clinical Trials Quality Monitor SOP Pages: 12 Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 17. Study Close Down According to ICH Good Clinical Practice (GCP)
More informationESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL
Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage
More informationMaintaining the blind for clinical trials in Pharmacy
York Foundation Trust R&D Unit SOP Pharm/S89 Maintaining the blind for clinical trials in Pharmacy IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO ENSURE THAT THE CORRECT VERSION IS BEING USED All
More informationConducting Clinical Trials of Investigational Medicinal Products
Title: Outcome Statement: Written By: Reviewed By: Conducting Clinical Trials of Investigational Medicinal Products Researchers in the Trust and research partners will be informed about the procedures
More informationDate: 2 nd June 2010 Version: 3 Page 1 of 16 AND LABELLING (NWORTH 3.08) Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10
Page 1 of 16 STANDARD OPERATING PROCEDURE FOR TRIAL SUPPLIES AND LABELLING (NWORTH 3.08) Approvals Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10 Quality Assurance Officer Name: D.
More informationTrial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products
1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationSTUDY REQUEST FORM AND TRAQ DSS FORM
Research Road Map April 2017 In This Issue Pharmacy Services for Research Study Request Form and TRAQ DSS FORM Management of Investigational Drugs Pharmacy Standard Operating Procedures IDS Team Qualifications
More informationThe purpose of these guidelines is to describe a standardized approach for the management of
ASHP Guidelines for the Management of Investigational Drug Products Purpose The purpose of these guidelines is to describe a standardized approach for the management of investigational drug products by
More informationStandard Operating Procedures
Standard Operating Procedures 5.14.1 Investigational Product Handling and Storage History Version Date Author Reason 1.1 23 rd August B Fazekas New procedure 2007 1.2 16 th October 2007 B Fazekas Update
More informationMAIMONIDES MEDICAL CENTER
MAIMONIDES MEDICAL CENTER CODE: AD-088 (Revised) ORIGINALLY ISSUED: October 2, 1990 SUBJECT: Product Safety Recall and Alert I POLICY In the event of a product safety recall or alert of a medical device
More informationR&D Administration Manager. Research and Development. Research and Development
Document Title: Document Number: Trial Closure and End of Trial SOP021 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D Administration
More informationStandard Operating Procedure for Archiving
Standard Operating Procedure for Archiving SOP name: NWORTH07/19 archiving Version 2 Authorship Team: Angela Gliddon & Rhiannon Whitaker Meeting date reviewed 16 th April 2008 Designated NWORTH member
More informationSTANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File
Research Department STANDARD OPERATING PROCEDURE STH Researcher SOP History CSUH 00/016 SOP Number A116 Created STH Research Department (TL) Reviewed by STH Research Department (AL) 06 August 2009 Superseded
More informationThe Right Prescription for Working with Investigational Drug Service at BMC
The Right Prescription for Working with Investigational Drug Service at BMC Andrew Schoch Pharmacy Intern Northeastern University Class of 2010 Hyeseon Hong, Pharm.D. IDS Pharmacy Manager What is Investigational
More informationTITLE: Research Pharmacy Standard Policy SOP #: INV-100 Page: 1 of 5 Effective Date: 8/31/17
SOP #: INV-100 Page: 1 of 5 1. POLICY STATEMENT: DF/HCC research pharmacies follow a standard set of policy requirements for clinical trials. 2. BACKGROUND: None 3. RESPONSIBLE PERSONNEL: 3.1. Research
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationNUH PHARMACY CLINICAL TRIALS. Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014
NUH PHARMACY CLINICAL TRIALS Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014 Dedicated pharmacy trials staff Lead Pharmacist, Service Co-ordinator Pharmacists: Band 7 and 8a Technicians:
More informationRDSOP28 Randomisation and Unblinding in Clinical Trials of an Investigational Medicinal Product (CTIMPs)
RDSOP28 Randomisation and Unblinding in Clinical Trials of an Investigational Medicinal Greater Manchester Mental Health NHS Foundation Trust Title of Standard Operating Procedure: Document Summary: Document
More informationDocument Title: Handling of drug alerts and recalls of IMPs
Document Title: Handling of drug alerts and recalls of IMPs Document Number: SOP074 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager,
More informationINVESTIGATIONAL PRODUCT ACCOUNTABILITY, STORAGE, DISPENSING, TRANSPORT AND RETURN
Policy/ Procedure # INVESTIGATIONAL PRODUCT ACCOUNTABILITY, STORAGE, DISPENSING, TRANSPORT AND RETURN 21 Effective Date June 2018 Category Global Last Review/Revision March 2017 Sub-Category Research Standards
More informationFDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
More informationOnce notified of the end of trial, a Research Manager, on behalf of the Sponsor, will contact the CI to arrange a close down monitoring visit.
1. INTRODUCTION This SOP has been produced in accordance with the requirements of The Medicines for Human Use (Clinical Trials) Regulations 2004, Medicines for Human Use (Clinical Trials) Amendment Regulations
More informationRegulatory Binder: Set-up and Maintenance
Regulatory Binder: Set-up and Maintenance Introduction Federal and state regulations, institutional policy, and good clinical and research practices require investigators to maintain documents related
More informationRDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust
RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs Greater Manchester Mental Health NHS Foundation Trust Title of Standard Operating Procedure: RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs
More informationCompliance and Quality Monitoring: What, Why, When, and How
Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University
More informationPREP Workshop # 20: Investigational Drug Accountability. Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS
PREP Workshop # 20: Investigational Drug Accountability Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS CME Disclosure Statement The North Shore LIJ Health System adheres
More informationStorage of Clinical Trials Materials and Investigational Medicinal Products
York Foundation Trust R&D Unit Standard Operating Procedure Pharm/S47 Storage of Clinical Trials Materials and Investigational Medicinal Products IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO ENSURE
More informationDRUG ORDERING AND MAINTENANCE
AND MAINTENANCE Disclaimer: Please note that the instructions provided in this chapter mainly apply to agents provided by the Pharmaceutical Management Branch (PMB), of Cancer Therapy Evaluation Program
More informationAnnex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO
23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,
More informationRegulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005
Regulatory Document Guidelines for DMID Clinical Studies Version 3.0-5-Oct-2005 1 Regulatory File Document Guidelines Purpose: To aid DMID supported Investigators in establishing a file of essential documents
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationQuality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)
Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations
More informationDrug Accountability. Kevin E. Anger PharmD, BCPS Manager Investigational Drug Services Brigham and Women s Hospital
Drug Accountability Kevin E. Anger PharmD, BCPS Manager Investigational Drug Services Brigham and Women s Hospital Session Objectives Define drug accountability and drugs in need of these accountability
More informationPOLICY Investigational Drug Service Transport
Investigational Drug Service Huntsman Cancer Hospital 1950 Circle of Hope, Suite 2110 Salt Lake City, Utah 84112 POLICY Investigational Drug Service Transport Purpose A. This policy establishes procedures
More informationJoint Research Office of Doncaster & Bassetlaw
Page 1 of 11 Hospitals NHS, Rotherham Doncaster & South Humber NHS and NHS Signatures: Role Name Function Date (DD-MM-YYYY) Signature Author Amy Beckitt Clinical Research Development Manager Reviewer Dr
More informationPOST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the
More informationInvestigator s Responsibility
Investigator s Responsibility Introduction Investigator s Qualifications Clinical Trial Agreement Adequate Resources Medical Care of Trial Subjects Communication with IRB/IEC Study Initiation Patient Recruitment
More informationRD SOP27 Implementing a Drug Recall for IMP/NIMP
RD SOP27 Implementing a Drug Recall for IMP/NIMP Version Number: Name of originator/author: Name of responsible committee: Name of executive lead: V3 Dr Andy Mee, R&I Manager and Maxine Syme, R&I Pharmacist
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Essential Documentation and Creation and Maintenance of Trial Master File SOP Number: 13 Version Number: 2.0 Supercedes:
More informationESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL
ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL THIS INFORMATION SHEET (ISR-RG-014) HAS BEEN TAKEN DIRECTLY FROM THE ICH- GUIDELINE* WITH ADDITIONAL COMMENTS ADDED BY THE RESEARCH GOVERNANCE
More informationGood Clinical Practice Inspections Expectations for Compliance with Sponsor Responsibilities, Part II
Good Clinical Practice Inspections Expectations for Compliance with Sponsor Responsibilities, Part II IMB Clinical Trials Seminar, 19 th June 2012 Ms. Sinead Curran GCP/Pharmacovigilance Inspector 22/06/2012
More informationStandard Operating Procedure
Standard Operating Procedure Number: UM/UoM TMF/SOP08/6.0 Title: The Creation and Maintenance of Trial Master Files and Essential Documentation Version: 6.0 () Effective Date: Author: Mrs Catherine Barrow
More informationPOINT Clinical Research Collaboration SOP-DH-CA.01 v2.0 POINT Trial Canadian Clinical Sites: Study Drug Handling Effective Date: 08/30/2013
TABLE OF CONTENTS 1. INTRODUCTION... 3 2. PURPOSE... 3 3. SCOPE... 3 4. RESPONSIBLE PERSONNEL AND CONTACT INFORMATION... 3 5. DEFINITIONS/ABBREVIATIONS AND RESOURCES... 5 6. PROCESS DETAIL DESCRIPTION...
More information(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION
21.3.2015 EN Official Journal of the European Union C 95/1 II (Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Guidelines of 19 March 2015 on
More informationStandard Operating Procedure. SOP effective: 19 February 2016 Review date: 19 February 2018
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-18-002 Randomisation and Code Breaking SOP effective: 19 February 2016 Review date: 19 February 2018 SOP author signature: SIGNED COPY HELD
More informationPharmacy Training Documents
Pharmacy Training Documents PiPS_EudraCT No: 2006-003445-17_REC REF: 09/H0604/30 Pharmacy Training Documents _Version 3.0 dated 30Jul10 Page 1 of 12 Top of pack gives instructions and information about
More informationMarie-Claire Good, RG and GCP Manager James Rickard, Deputy Chief Pharmacist Technical Services Cheryl Lawrence, Senior Research Pharmacist
Standard Operating Procedures (SOP) for: IMP Management BH/QMUL Sponsored CTIMPs SOP Number: 42a Version Number: 3.0 Effective Date: 14 th August 2017 Review Date: 14 th August 2019 Author: Reviewer: Reviewer:
More informationVOLUME 4 Good manufacturing practices ANNEX 13 Manufacture of investigational medicinal products JULY 2003
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, F2/BL D(2003) Revision
More informationCode of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products
Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products March 2014 Table of Content INTRODUCTION 3 Section 1: GENERAL RESPONSIBILITIES OF HOLDER
More informationGUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 047-1 Annex 1 July 2018 GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL
More informationDevelopment Safety Update Report Guidance
Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationANCHOR ISO9001:2008 RPR-007 MARINE SERVICES ADDITIONAL PROCEDURE PRODUCT REALISATION
PRODUCT REALISATION Document Control Revision History PAGE REASON FOR CHANGE REV. REVIEWER / AUTHORISED BY: RELEASE DATE: ALL NEW DOCUMENT A J.BENTINK 5/08/2016 Revision Approval: J.BENTINK Signature:
More informationRESEARCH AUDIT Standard Operating Procedure
Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor
More informationDRUG ORDERING AND MAINTENANCE
AND MAINTENANCE Disclaimer: Please note that the instructions provided in this chapter only apply to agents provided by the Pharmaceutical Management Branch (PMB), of Cancer Therapy Evaluation Program
More informationNHS Tayside Effective Date: 24/7/2009
1. PURPOSE This document describes the procedure for the supply, transport and storage of Investigational Medicinal Product (IMP). This SOP complies with the principles of Good Clinical Practice, Good
More informationQUALITY AGREEMENT. The following Agreement has been concluded between
QUALITY AGREEMENT The following Agreement has been concluded between LLC LABORATORIES The contract laboratory and service provider 1625 Trinity Dr., Unit 11 Mississauga, Ontario Canada L5T 1W9 Hereinafter
More informationClinical Trial Unit, Hospital Pharmacy Central Denmark Region
Clinical Trial Unit, Hospital Pharmacy Central Denmark Region Letter of Introduction The aim of this Letter of Introduction is to clarify general guidelines for working with the Hospital Pharmacy Central
More informationDate: 23 rd December 2014 Version 5 Page 1 of 8 STANDARD OPERATING PROCEDURE FOR TRIAL INITIATION AND SITE SET UP (NWORTH 3.03)
Page 1 of 8 STANDARD OPERATING PROCEDURE FOR TRIAL INITIATION AND SITE SET UP (NWORTH 3.03) Approvals Principal Author Name: D. Skelhorn Signature: D. Skelhorn Date: 22/12/2014 Quality Assurance Officer
More informationResearch Study Close-down and Archiving Procedures
Title: Research Study Close-down and Archiving Procedures Outcome Statement: To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationTemperature Monitoring (Clinical Trials)
York Foundation Trust R&D Unit Standard Operating Procedure Pharm/S48 Temperature Monitoring (Clinical Trials) IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO ENSURE THAT THE CORRECT VERSION IS BEING
More informationOFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out
OFFICE FOR RESEACH PROCEDURE Site Initiation and Close-out 1. Purpose: To describe the procedures related to site initiation and close-out of a clinical trial. 2. Scope: Applicable to all phases of clinical
More informationImplications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials
Implications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials Lisa Marie Saldanha Senior Director & Head Academic Research & Delivery Solutions Real World Insights
More informationSTANDARD OPERATING PROCEDURE SOP 410. Set up and Initiation of an Investigator Site
STANDARD OPERATING PROCEDURE SOP 410 Set up and Initiation of an Investigator Site Version 1.2 Version date 4.01.2017 Effective date 5.07.2017 Number of pages 13 Review date July 2019 Author Role NNUH
More informationSource Documents and Regulatory Binders October 6, 2016
Source Documents and Regulatory Binders October 6, 2016 Lisa Wilson, Regulatory Lead, Clinical Trials Office and Mark Alger, CRC, Clinical Trials Office Essential Documents AKA: the stuff in the Reg Binder
More informationIND Drug Log Guidelines
9/24/2009 IND Drug Log Guidelines 1) An NCI DARF (Drug Accountability Record Form) should be kept on each strength of investigational drug. An investigational drug is considered to be any drug (including
More informationStandard Operating Procedure. GCP Auditing of Research Studies
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-16-003 GCP Auditing of Research Studies SOP effective: 09 June 2017 Review date: 09 June 2019 SOP author signature: SIGNED COPY HELD WITHIN
More informationSTANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA
STANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA SOP#: 014.5 Date Issued: 11/00 Date Revised: 8/15 Page 1 of 5 TITLE: SCOPE: RESPONSIBILITY: PURPOSE: Research
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
Ref. Ares(2013)148102-05/02/2013 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, SANCO/D/6/SF/mg/ddg1.d.6(2013)179367
More informationSite Initiation and Activation
Site Initiation and Activation Clinical Trials SOP Reference ID: Noclor/Spon/S05/01 Version Number 1.0 Effective Date: 23 rd February 2016 It is the responsibility of all users of this SOP to ensure that
More informationEnd of Study Notification, Close-Out and Reporting Sponsored Research. Noclor/Spon/S11/01. SOP Reference ID:
End of Study Notification, Close-Out and Sponsored Research SOP Reference ID: Noclor/Spon/S11/01 Version Number 1.0 Effective Date: 6 th June 2016 It is the responsibility of all users of this SOP to ensure
More informationGUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS
1. PURPOSE This guideline is about the collection, verification, and submission of the reports of adverse events / reactions occurring in clinical drug trials, and code breaking methods. 2. DEFINITIONS
More informationStandard Operating Procedure
Standard Operating Procedure Title: Clinical Site Monitoring Status: PRIVATE Author Name: Audrey Strader Approver Name: Christine Kubiak Document no.: CSM 02 Effective date: 11/01/2016 Review Date (if
More informationTrial Protocol. Version 1.2. Effective date: 18 May Dr Sarah Duggan, CTU Manager. V May 2010 Update web links.
Trial Version 1.2 Effective date: 18 May 2010 Reviewed by: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Reason for change V1.2 18 May 2010 Update
More informationKingston Health Sciences Centre Pharmacy Services Investigational Drug Service (IDS) COST ESTIMATE REQUEST FORM Version July 2017
Please complete the KHSC Pharmacy Services Study Request Form and ATTACH the Form to your TRAQ DSS FORM prior to submission. If you forgot to attach the Form to your TRAQ DSS FORM prior to submission,
More informationKingston Health Sciences Centre Pharmacy Services Investigational Drug Service (IDS) COST ESTIMATE REQUEST FORM Version June 2018
Please complete the KHSC Pharmacy Services Study Request Form and ATTACH the Form to your TRAQ DSS FORM prior to submission. If you forgot to attach the Form to your TRAQ DSS FORM prior to submission,
More information